Latest news with #IndocoRemedies
Time of India
3 days ago
- Business
- Time of India
Initiative appointed as Media Agency on Record for Sensodent
Initiative has been appointed as the media agency on record for Sensodent , a specialised oral care brand from Indoco Remedies , a Mumbai-based pharmaceutical company. As Sensodent gears up to strengthen its leadership in the oral sensitivity segment, Initiative will lead the brand's media strategy, planning, and deployment across platforms—focusing on driving awareness, trials, and brand relevance at scale. The media mandate was awarded following a multi-agency pitch process . Commenting on this development, Aditi Panandikar, managing director, Indoco Remedies said, 'Our brand Sensodent is the first to go OTC and over the year has evolved into the next orbit. We are thrilled to work together with Initiative and are looking forward to see our brand soaring newer heights.' Dhirendra Singh, executive vice president and head – Mumbai, Initiative, said, "Sensodent K is a high-potential brand in a growing yet underpenetrated category. We're excited to partner with Indoco Remedies to architect a media approach that drives performance, builds cultural relevance, and connects meaningfully with consumers across India." Speaking on the partnership, Vaishali Verma, chief executive officer, Initiative India, said, "We welcome Sensodent into the Initiative family. We look forward to a strong partnership focused on driving brand success and creating meaningful work."
Business Upturn
3 days ago
- Business
- Business Upturn
Indoco Remedies launches Ticagrelor tablets in UK through subsidiary
By Aditya Bhagchandani Published on June 3, 2025, 13:06 IST Indoco Remedies Limited has officially launched its Ticagrelor film-coated tablets (90mg) in the United Kingdom through its subsidiary, Indoco Remedies UK Limited, on June 2, 2025. This marks a significant development for the company as it expands its international portfolio in the antiplatelet medication segment. The newly launched product is aimed at reducing the risk of heart attacks, strokes, and other cardiovascular complications. It will be marketed and distributed across the UK by Clarity Pharma. Commenting on the development, Aditi Kare Panandikar, Managing Director of Indoco Remedies, said, 'This development underscores our commitment to bringing high quality, life-saving treatments to patients in the UK.' Indoco Remedies is a fully integrated pharmaceutical company with a global presence and a turnover of USD 180 million. The company has 11 manufacturing facilities and over 6,000 employees. It operates in various therapeutic segments, including gastrointestinal, respiratory, anti-infectives, and cardiovascular care, among others. The UK launch of Ticagrelor further strengthens Indoco's footprint in the international market and reinforces its commitment to expanding its presence in regulated markets. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
&w=3840&q=100)
Business Standard
23-05-2025
- Business
- Business Standard
What drove Indoco Remedies share price 6% higher today? Top details inside
Indoco Remedies share price: Pharmaceutical company Indoco Remedies shares rose as much as 6.38 per cent to hit an intraday high of Rs 258.20 per share on Friday, May 23, 2025. At 12:10 PM, Indoco Remedies share price was trading 1.77 per cent higher at Rs 247. In comparison, BSE Sensex was trading 0.90 per cent higher at 81,678.93 level. Why did Indoco Remedies share price rise? Indoco Remedies share price rose after the company announced that it has secured final approval of Allopurinol Tablets USP, 200 mg through Company's Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP to market a generic equivalent to the reference listed drug (RLD), Zyloprim 200 mg of Casper Pharma LLC from USFDA.' Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones. Aditi Panandikar, managing director of Indoco Remedies, said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' The product will be manufactured by Indoco Remedies Limited at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa – 403722 in India, the company revealed. About Indoco Remedies Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a robust global footprint. With a turnover of approximately $180 million, the company is supported by a talented workforce of over 6,000 employees, including more than 400 scientists and an extensive field force. These professionals form the backbone of Indoco's operations, driving innovation and ensuring the delivery of high-quality pharmaceutical products. The company operates 11 state-of-the-art manufacturing facilities—seven dedicated to finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs)—along with a cutting-edge R&D centre and a Contract Research Organization (CRO) facility. These facilities are approved by major global regulatory agencies, including the USFDA and UKMHRA. Indoco serves both domestic and international markets, generating over 106 million prescriptions annually through a network of more than 2,40,000 doctors across various specialties. Domestically, it operates through 10 marketing divisions and offers a strong brand portfolio spanning multiple therapeutic areas such as gastroenterology, respiratory care, anti-infectives, ophthalmology, nutrition, cardiology, diabetology, pain management, and gynecology. Some of Indoco's flagship brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Glychek. Globally, Indoco partners with leading generic pharmaceutical companies, further strengthening its presence in international markets.
Business Standard
23-05-2025
- Business
- Business Standard
Indoco Remedies gains after receiving USFDA nod for Allopurinol drug
Indoco Remedies rose 1.28% to Rs 245.80 after the company announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Allopurinol tablets. Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones. The drug is the generic equivalent of the reference listed drug (RLD), Zyloprim, marketed by Casper Pharma LLC. Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The pharmaceutical company reported a standalone net loss of Rs 10.23 crore in Q3 FY25 as against a net profit of Rs 20.01 crore posted in Q3 FY24. Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24.
Business Standard
23-05-2025
- Business
- Business Standard
Indoco Remedies reports consolidated net loss of Rs 40.39 crore in the March 2025 quarter
Sales decline 12.57% to Rs 383.89 crore Net loss of Indoco Remedies reported to Rs 40.39 crore in the quarter ended March 2025 as against net profit of Rs 22.70 crore during the previous quarter ended March 2024. Sales declined 12.57% to Rs 383.89 crore in the quarter ended March 2025 as against Rs 439.08 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 73.74 crore in the year ended March 2025 as against net profit of Rs 98.47 crore during the previous year ended March 2024. Sales declined 8.22% to Rs 1641.29 crore in the year ended March 2025 as against Rs 1788.22 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 383.89439.08 -13 1641.291788.22 -8 OPM % -0.2011.13 - 6.0513.66 - PBDT -16.7439.48 PL 38.48216.14 -82 PBT -45.5213.25 PL -75.36124.27 PL NP -40.3922.70 PL -73.7498.47 PL
